Protara Therapeutics (TARA) Common Equity (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Common Equity data on file, last reported at $181.2 million in Q1 2026.

• On a quarterly basis, Common Equity rose 14.34% year-over-year to $181.2 million in Q1 2026; TTM through Mar 2026 was $181.2 million, a 14.34% increase from a year earlier, with the FY2025 full-year figure at $196.4 million, up 17.52% from the prior year.
• Common Equity for Q1 2026 stood at $181.2 million, down from $196.4 million in the prior quarter.
• Over the last five years, Common Equity for TARA reached as high as $196.4 million in Q4 2025 and fell as low as $58.4 million in Q1 2024.
• Historically, Common Equity has averaged $122.1 million across 5 years, with a median of $132.3 million in 2025.
• Across the five-year window, Common Equity tumbled 44.71% in 2023 and soared 171.35% in 2025, its largest moves.
• Year by year, Common Equity stood at $102.1 million in 2022, then plunged by 33.07% to $68.3 million in 2023, then jumped by 144.63% to $167.1 million in 2024, then climbed by 17.52% to $196.4 million in 2025, then retreated by 7.74% to $181.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $181.2 million in Q1 2026, $196.4 million in Q4 2025, and $132.3 million in Q3 2025.